Edition:
United Kingdom

AnaptysBio Inc (ANAB.OQ)

ANAB.OQ on NASDAQ Stock Exchange Global Select Market

91.67USD
20 Apr 2018
Change (% chg)

$0.80 (+0.88%)
Prev Close
$90.87
Open
$90.39
Day's High
$92.55
Day's Low
$90.00
Volume
91,314
Avg. Vol
143,381
52-wk High
$134.00
52-wk Low
$18.18

Chart for

About

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro,... (more)

Overall

Beta: --
Market Cap(Mil.): $725.82
Shares Outstanding(Mil.): 20.34
Dividend: --
Yield (%): --

Financials

  ANAB.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.06 -- --
ROI: -23.31 1.58 14.38
ROE: -48.33 2.41 16.07

BRIEF-Anaptysbio Announces Positive Top-Line Proof-Of-Concept Data For ANB020 In Moderate-To-Severe Baseline Adult Peanut Allergy Patients

* ANAPTYSBIO ANNOUNCES POSITIVE TOP-LINE PROOF-OF-CONCEPT DATA FOR ANB020 IN MODERATE-TO-SEVERE BASELINE ADULT PEANUT ALLERGY PATIENTS

26 Mar 2018

BRIEF-AnaptysBio Qtrly ‍Loss Per Share $0.30

* ANAPTYSBIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND 2018 PIPELINE MILESTONES

05 Mar 2018

BRIEF-Anaptysbio qtrly loss per share $0.45‍​

* Anaptysbio announces third quarter 2017 financial results and provides pipeline updates

07 Nov 2017

BRIEF-AnaptysBio reports positive ANB019 top-line phase 1 clinical trial results

* Anaptysbio reports positive anb019 top-line phase 1 clinical trial results

06 Nov 2017

Earnings vs. Estimates